arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

INTEGRA LIFESCIENCES HOLDINGS CORP

IART
$17.25 ▲ +0.16 (+0.97%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
72 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

INTEGRA LIFESCIENCES HOLDINGS CORP faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.3B
Dividend Yield
Revenue Growth 0.8%
Op. Margin 4.6%
ROIC 1.0%
FCF / Share $0.14
Trailing P/E 287.5x
Price / Book 1.3x
FCF Yield 0.8%
Debt / Equity 0.68
info Valuation on last close. End-of-day price, Aug 7, 2026.

72-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$418.76M
↑ +0.8%
Net Income Profit after all expenses
$-4.62M
↑ +81.7%
Operating Margin Operating profit as % of sales
4.6%
↑ +57.4% 8th
FCF / Share Free cash flow per share
$0.14
↑ +307.1%
Long-Term Debt Long-term obligations
$707.19M
↓ -1.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
12
Returns
17
Financial Health
40
Cash Quality
24

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 19 years · 72 quarters